Targeting the IL34-CSF1R axis improves metastatic renal cell carcinoma therapy outcome via immune-vascular crosstalk regulation

Targeting the IL34-CSF1R axis improves metastatic renal cell carcinoma therapy outcome via immune-vascular crosstalk regulation

Summary: Current therapies ultimately fail to eradicate metastatic renal cell carcinoma (RCC). Validated biomarkers and a better understanding of the mechanisms causing therapy resistance are still needed. Here we demonstrate that interleukin-34 (IL34) is associated with poor prognosis, metastasis,...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea Emanuelli, Wilfried Souleyreau, Tiffanie Chouleur, Bram Boeckx, Yasmine Pobiedonoscew, Lindsay Cooley, Marie-Alix Derieppe, Julie Martineau, Damien Ambrosetti, Jean-Christophe Bernhard, Catherine M. Sawai, Diether Lambrechts, Thomas Mathivet, Andreas Bikfalvi
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:iScience
Subjects:
Molecular biology
Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004225010132
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2589004225010132

Similar Items